Rovi

Spanish Pharmaceutical Company

BME Madrid ISIN ES0157261019 LEI 95980020140005936480
Follow Rovi Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €743.5M −2.7% vs prior year
Net income €140.4M +2.6% vs prior year
EPS, diluted €2.75 +3% vs prior year
Operating cash flow €187.1M +35.3% vs prior year
Revenue by fiscal year
€420M
€648.7M
€817.7M
€829.5M
€763.7M
€743.5M
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income6 fiscal years
  • Revenue
  • Net income
€0€250M€500M€750M€1BFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€743.5M€140.4M
FY24€763.7M€136.9M
FY23€829.5M€170.3M
FY22€817.7M€199.7M
FY21€648.7M€153.1M
FY20€420M€61.1M
MarginsShare of revenue
  • Operating margin
  • Net margin
0%10%20%30%40%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY2525%18.9%
FY2423.5%17.9%
FY2326.6%20.5%
FY2231.3%24.4%
FY2128%23.6%
FY2017.8%14.5%
Free cash flowOperating cash flow minus capital expenditure
€0€50M€100M€150M€200MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25€121.9M
FY24€79.2M
FY23€59.5M
FY22€186.9M
FY21€109.2M
FY20€7.5M
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
€0€100M€200M€300MFY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25€47.8M€54.9M
FY24€56.5M€89.7M
FY23€69M€133.9M
FY22€51M€177M
FY21€21.1M€78.8M
FY20€9.7M€37.3M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Rovi
  • Healthcare median
−100%−50%0%50%FY20FY21FY22FY23FY24FY25
Show the numbers
YearRoviHealthcare median
FY2518.9%−30.6%
FY2417.9%−47%
FY2320.5%−58%
FY2224.4%−80.4%
FY2123.6%−71.9%
FY2014.5%−62.2%